FTC lays out road map for merger review in overhaul of decade-old antitrust framework
After spending the year testing its expansive new views on mergers in the life sciences industry, the FTC has finalized new guidance for reviewing deals reflecting the agency’s tougher stance against what it calls “harmful corporate consolidation.”
While the framework isn’t legally binding, it’s meant to shed some light on the FTC’s antitrust decision-making. That includes its increased scrutiny of pharma deals, which this year led to a monthslong battle over Amgen’s $28 billion Horizon takeover, a recently dropped deal between Sanofi and Maze, and the just-ended fight over Illumina’s takeover of Grail.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
